Table 1.
Demographic and baseline characteristics (intention-to-treat set)
| Placebo (n = 77) | DA-8010 2.5 mg (n = 76) | DA-8010 5 mg (n = 77) | Solifenacin 5 mg (n = 76) | Total (n = 306) | |
|---|---|---|---|---|---|
| Age (yr) | 59.48 ± 14.95 (63.00) | 58.21 ± 13.12 (62.00) | 60.73 ± 12.12 (62.00) | 59.05 ± 13.72 (61.00) | 59.37 ± 13.48 (62.00) |
| Male sex | 24 (31.17) | 22 (28.95) | 23 (29.87) | 23 (30.26) | 92 (30.07) |
| Height (cm) | 160.03 ± 8.79 (158.00) | 161.18 ± 7.21 (159.10) | 160.72 ± 8.03 (160.00) | 161.19 ± 7.55 (160.30) | 160.78 ± 7.89 (159.55) |
| Weight (kg) | 61.81 ± 10.21 (59.00) | 64.26 ± 10.94 (63.15) | 62.78 ± 9.19 (61.40) | 63.59 ± 10.73 (62.40) | 63.11 ± 10.2 (61.80) |
| Body mass index (kg/m2) | 24.10 ± 3.23 (24.04) | 24.71 ± 3.73 (24.05) | 24.25 ± 2.63 (24.09) | 24.48 ± 3.90 (24.07) | 24.38 ± 3.40 (24.06) |
| Duration of OAB symptoms (mo) | 65.87 ± 89.42 (27.07) | 57.50 ± 63.79 (26.94) | 66.86 ± 110.46 (28.22) | 67.74 ± 102.29 (39.10) | 64.51 ± 92.86 (30.54) |
| Experience of OAB treatment prior to screening | 17 (22.08) | 19 (25.00) | 21 (27.27) | 22 (28.95) | 79 (25.82) |
| Overall urinary incontinence | 37 (48.05) | 35 (46.05) | 37 (48.05) | 35 (46.05) | 144 (47.06) |
| Urgency urinary incontinence | 37 (48.05) | 36 (47.37) | 35 (45.45) | 36 (47.37) | 144 (47.06) |
Values are presented as mean±standard deviation (median) or number (%).
OAB, overactive bladder.